We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
FDA批准pivekimab sunirin（Decnupaz）用于BPDCN，完全缓解率达69.7%。分析疗效、风险、价格及在AML中的前景。了解更多。
